Hematuria Treatment Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Johnson & Johnson, Cipla Ltd, Pfizer Inc., Aurobindo Pharma USA, Zambon USA Ltd., GlaxoSmithKline plc

Hematuria Treatment Market is estimated to grow at a CAGR 2.8% during the forecast period 2024-2031.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/hematuria-treatment-market?sg

Industry Recent Developments 2025:

✅ 12 Jun 2025 - FDA approves UroGen's intravesical mitomycin product ZUSDURI (first FDA-approved mitomycin intravesical solution for recurrent low-grade, intermediate-risk NMIBC).

✅ 27 Feb 2025 - AUA/SUFU publishes the 2025 Microhematuria Guideline Amendment (refines risk stratification and, for the first time, permits use of validated urine-based tumor markers in appropriately counseled intermediate-risk patients).

✅ 28 Feb 2025 - Pacific Edge / Cxbladder announcement: Cxbladder Triage is specifically named in the AUA microhematuria amendment and described as the urine biomarker with highest supporting evidence ("Grade A" in the guideline context).

✅ 29 Apr 2025 - AUA 2025 plenary/conference reports: real-world evaluations (Kaiser Permanente and others) and presentations showing Cxbladder Triage/Triage Plus utility in triaging hematuria patients - strengthens clinical uptake of urine-based diagnostics to reduce unnecessary cystoscopy.

✅ 24 Mar 2025 - EAU 2025 highlights: EpiCheck-triggered photodynamic diagnosis and other enhanced cystoscopy adjuncts were presented as methods that detect high-grade recurrences missed by standard white-light cystoscopy - relevant to hematuria diagnostic pathways.

✅ 9 Apr 2025 - Growth-equity activity: General Atlantic makes a growth investment in U.S. Urology Partners (strengthening practice consolidation / MSO networks that influence referral patterns and service delivery for hematuria evaluation).

✅ (Apr-Jun 2025) Diagnostics & imaging vendor momentum: multiple vendors showcased upgraded cystoscopy/ureteroscopy imaging systems and noninvasive urine-test validation data across conferences in 2025 industry push to de-intensify invasive hematuria workups where appropriate.

✅ 12 Aug 2025 - (major MSO deal affecting urology care consolidation) Cardinal Health announced agreement to acquire Solaris Health (a large urology MSO) - transaction expands multi-specialty/MSO footprints that will affect urology service networks and hematuria care delivery.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hematuria-treatment-market?sg

Key market growth drivers:

✅ Rising prevalence of urological disorders & ageing populations - growing incidence of bladder cancer, recurrent UTIs, kidney stones and age-related urologic conditions increases demand for hematuria diagnosis and treatment.

✅ Improved diagnostics and minimally invasive therapies - wider adoption of cystoscopy (including single-use cystoscopes), advanced imaging and endoscopic treatments raises diagnosis rates and expands treatment pathways.

✅ Greater awareness and screening / earlier detection - screening programs and guideline-driven evaluation of microscopic/macroscopic hematuria lead to more investigations and downstream treatment interventions.

✅ R&D, pipeline activity and device innovation - investment in urology devices, disposable/endoscopic tools and therapeutic pipelines supports market expansion and creates new commercial opportunities.

Regional share & dynamics:

➠ North America - largest share (~~35-40%): The United States leads because of advanced healthcare infrastructure, high healthcare spend, established urology centers and broad adoption of diagnostic/therapeutic technologies. Several market reports identify North America as the dominant regional market.

➠ Europe - second largest: Strong clinical research activity, reimbursement coverage and demand for novel therapies keep Europe as a major market (notably Germany, UK, France).

➠ Asia-Pacific - fastest-growing: Higher unmet need, expanding healthcare access, rising disease burden and investments in diagnostics make APAC the fastest-growing region (China and India singled out by several sources).

Segments Covered in the Hematuria Treatment Market:

By Type (Drugs, Therapies)

By Disease Type (Microscopic Hematuria, Gross Hematuria)

By End-User (Hospitals, Specialty Clinics, Other)

Regional Analysis for Hematuria Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=hematuria-treatment-market?sg

Major Key Players: Johnson & Johnson, Cipla Ltd., Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Pfizer Inc., Aurobindo Pharma USA, Zambon USA Ltd., GlaxoSmithKline plc.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.